Canaloplasty an option after failed trabeculectomy

Article

If initial trabeculectomy has failed, canaloplasty can be an option, according to Dr Brusini

A perfectly performed trabeculectomy can fail to lower intraocular pressure (IOP), even if mitomycin C has been used, because of pre-existing conjunctival scarring. If this is the case, a second trabeculectomy will seldom provide adequate IOP control for precisely the same reasons that caused the initial surgical failure. Typically, either the implant of a tube or a diode laser cyclophotocoagulation would be recommended as the next step for treating these cases, but both of these options entail several possible serious complications. Therefore, an alternative surgical option for treating glaucoma is essential.

Although it is normally indicated for eyes that have not undergone previous filtrating surgery for glaucoma, canaloplasty is a viable alternative surgical option for a select number of eyes in which postoperative gonioscopic examination shows that the initial 'trabeculectomy' had been performed anterior to the trabecular structures - in other words, had in fact been a sclero-keratectomy - and that Schlemm's canal had been left intact. This scenario is now seen more frequently, especially in eyes in which an emport-piece trabeculectomy is associated with a one-site phacoemulsification.

As canaloplasty is not dependent on conjunctiva status for proper functioning, it is an appropriate treatment in these eyes, particularly in cases where IOP remains elevated despite maximum tolerated medical therapy and therefore further surgery is indicated.

"A mandatory prerequisite for this surgery is an apparently intact Schlemm's canal at gonioscopy," he notes. "The presence of peripheral anterior synechiae or previous argon laser trabeculoplasty can affect the success of canaloplasty, making it difficult or sometimes impossible to perform cannulation; however, these should not be considered as absolute contraindications for this procedure."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.